NovoCure Limited - Ordinary Shares (NQ:NVCR)

15.20 +0.26 (+1.74%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Novocure Reports First Quarter 2023 Financial Results

May 04, 2023

From Novocure

Via Business Wire

The 3 Most Promising Healthcare Tech Stocks for April 2023 ↗

April 26, 2023

The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector.

Via InvestorPlace

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2023

From Novocure

Via Business Wire

Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

April 14, 2023

From Novocure

Via Business Wire

What 4 Analyst Ratings Have To Say About NovoCure ↗

March 17, 2023

Via Benzinga

2 Best Defensive Stocks to Buy in March ↗

March 08, 2023

These two defensive stocks should shine in the event of a marketwide correction.

Via The Motley Fool

Novocure to Report First Quarter 2023 Financial Results

April 03, 2023

From Novocure

Via Business Wire

Kristin Stafford Joins Novocure Board of Directors

March 29, 2023

From Novocure

Via Business Wire

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

March 16, 2023

From Novocure

Via Business Wire

NovoCure Earnings Perspective: Return On Capital Employed ↗

February 27, 2023

Via Benzinga

Why NovoCure Stock Is Falling Today ↗

February 23, 2023

Investors were looking for a stronger Q4 from the cancer company.

Via The Motley Fool

NovoCure (NVCR) Q4 2022 Earnings Call Transcript ↗

February 23, 2023

NVCR earnings call for the period ending December 31, 2022.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 ↗

March 17, 2023

Via Benzinga

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

March 01, 2023

From Novocure

Via Business Wire

Why Novocure Stock Was so Healthy Today ↗

February 15, 2023

There was good news from the laboratory on Hump Day.

Via The Motley Fool

Why Novocure Stock Is Sliding Today ↗

January 19, 2023

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

Via The Motley Fool

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

March 01, 2023

From Novocure

Via Business Wire

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 23, 2023

From Novocure

Via Business Wire

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

February 23, 2023

From Novocure

Via Business Wire

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 15, 2023

From Novocure

Via Business Wire

Will Novocure Stock Sink or Soar in 2023? ↗

January 19, 2023

The stock has both soared and sank already this year.

Via The Motley Fool

Why Novocure Stock Is Sinking Today ↗

January 09, 2023

The company provided a disappointing sneak peek at its Q4 results.

Via The Motley Fool

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes ↗

January 19, 2023

A series of unexpected C-suite changes sent shares diving again.

Via Investor's Business Daily

Novocure Announces Organizational Changes to Prepare for Future Growth

January 19, 2023

From Novocure

Via Business Wire

Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace ↗

January 17, 2023

Shares have given back a chunk of their 69% single-day gain on a lung cancer study.

Via Investor's Business Daily

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

January 09, 2023

From Novocure

Via Business Wire

Is NovoCure a Good Stock to Buy Right Now? ↗

January 07, 2023

Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?

Via The Motley Fool

Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review ↗

January 06, 2023

The major indexes rallied Friday on the jobs report and services data.

Via Investor's Business Daily

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.